GLP-1 receptor agonists

GLP-1 receptor agonists are drugs that activate the receptor for glucagon-like peptide-1, a hormone released by the gut after a meal; most are engineered peptides rebuilt to survive in the bloodstream for days rather than minutes. They lower blood glucose, slow gastric emptying, and act on brainstem and hypothalamic circuits to reduce food intake, and in adults with obesity the newer agents produce weight loss that no earlier drug approached. Whether that makes them a longevity intervention is the argument this article is about: they demonstrably treat conditions that shorten life, and nothing shows that they change the rate at which anyone ages.

§How they work

GLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon when nutrients arrive. It amplifies insulin release in a glucose-dependent way, which is why these drugs rarely cause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and it binds receptors in the hypothalamus and the area postrema, where the signal registers as satiety.¹ The native peptide is destroyed within a few minutes by the enzyme DPP-4, so the therapeutic problem was never finding the hormone but making it last.

Two solutions dominate. The first came from a lizard: exendin-4, isolated from Gila monster venom, is naturally resistant to DPP-4 and activates the human receptor, and became exenatide.² The second is chemical modification of the human sequence, combining amino-acid substitutions with a fatty-acid chain that binds circulating albumin and slows both enzymatic degradation and renal clearance. That combination makes liraglutide a once-daily injection and semaglutide a once-weekly one.

Most of the weight loss follows from eating less. That resemblance to a caloric deficit is what first drew attention from biogerontology, though the analogy to Caloric restriction is loose: dietary restriction experiments hold lean animals below their normal intake, while these drugs mainly remove excess adiposity from people who have it. Whether any of the cardiovascular or renal benefit is independent of weight loss is actively researched and unsettled.

Terminology

GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempic for type 2 diabetes and Wegovy for weight management, acts at the GLP-1 receptor only, as do liraglutide, dulaglutide, and exenatide. Tirzepatide, Eli Lilly's Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist and is not a GLP-1 agonist in the strict sense; retatrutide adds a glucagon receptor arm. Press coverage collapses all of these into "GLP-1s", which obscures real pharmacological differences.

§Development history

1. 1987
   Incretin action established
   Work in several laboratories shows that the GLP-1 fragment released after eating stimulates insulin secretion, identifying it as a physiological incretin.
2. 1992
   Exendin-4 isolated
   John Eng and colleagues characterize a DPP-4-resistant GLP-1 receptor agonist in the venom of the Gila monster, the peptide that becomes exenatide.
3. 2005
   First approval
   Exenatide is approved in the United States for type 2 diabetes, twice-daily by injection.
4. 2010
   Liraglutide reaches market
   Novo Nordisk's daily analogue is approved for type 2 diabetes; a higher-dose version is approved for weight management in 2014.
5. 2016
   Cardiovascular benefit in diabetes
   The LEADER trial reports fewer major cardiovascular events with liraglutide in people with type 2 diabetes at high cardiovascular risk.
6. 2017
   Semaglutide approved
   The once-weekly analogue is approved for type 2 diabetes; an oral tablet formulation follows in 2019.
7. 2021
   Obesity result and shortage
   STEP 1 reports roughly 15 percent mean weight loss over 68 weeks and semaglutide is approved for weight management; demand outstrips manufacturing capacity for the next several years.
8. 2022
   Dual agonism
   Tirzepatide, targeting both the GIP and GLP-1 receptors, is approved for type 2 diabetes; SURMOUNT-1 reports mean weight loss around a fifth of body weight at the highest dose.
9. 2023
   Outcomes without diabetes
   SELECT reports fewer major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease but no diabetes; tirzepatide is approved for obesity.
10. 2024
    Beyond weight and glucose
    The FLOW trial, halted early for efficacy the previous year, reports slower kidney-disease progression with semaglutide in type 2 diabetes. Labels expand toward cardiovascular risk reduction and, for tirzepatide, obstructive sleep apnoea.

§What the trials show

The weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults with overweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68 weeks on semaglutide, against about 2 percent on placebo.³ Tirzepatide, at its highest dose in SURMOUNT-1, averaged around a fifth.⁴ Means conceal a wide spread: a substantial minority lose very little, and both trials gave every participant diet and activity counselling alongside the injection.

The strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes, and reported a relative reduction of roughly a fifth in a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke over about three years.⁵ The absolute difference was a small number of percentage points, in a population already at high risk. Deaths from any cause were fewer in the treated group, a difference the trial's statistical hierarchy did not establish as a confirmed result. Regulators subsequently expanded semaglutide's label to cardiovascular risk reduction.

Other organ systems have followed. Semaglutide slowed progression of kidney disease in people with type 2 diabetes and chronic kidney disease.⁶ Trials have reported improved symptoms in heart failure with preserved ejection fraction, reduced severity of obstructive sleep apnoea with tirzepatide, and reduced knee osteoarthritis pain. The failures matter as much: Novo Nordisk reported in late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slow progression of the disease, the most direct test so far of the claim that incretin drugs act broadly on age-related disease rather than through metabolism.⁷

§The geroscience argument

The case for treating this class as a longevity intervention is a population argument rather than a biological one. Obesity and type 2 diabetes are among the largest modifiable contributors to premature death, and they accelerate several of the Hallmarks of aging: chronic low-grade inflammation of the kind described under Inflammaging, accumulation of senescent cells in adipose tissue as covered under Cellular senescence, vascular and renal damage. A drug that reverses those at scale could move population life expectancy further than any candidate geroprotector now in trials has any prospect of doing, which is the The longevity dividend argument arriving from an unexpected direction. Proponents add that one agent delaying several apparently unrelated age-related conditions is the shape of result the Geroscience hypothesis predicts, and the shape the TAME trial was designed to produce.

The case against is that this is disease treatment doing what disease treatment does. Restoring someone with obesity toward the metabolic state of someone who never had it returns them to a baseline; it does not push past it. Nothing in the record shows a change in the underlying rate of aging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weight endpoints rather than lifespan. The distinction is exactly the one that separates this class from Rapamycin and the other candidate geroprotectors, whose whole claim is that they act on aging upstream of any particular disease. On the evidence to date, GLP-1 agonists remove an accelerator; they do not slow the clock.

Removing an accelerator or slowing the clock

If the whole benefit runs through weight and glucose, these are excellent drugs for two diseases and say nothing about aging. If part of it is direct receptor signalling in vessels, kidney, and brain, they belong in the geroprotector conversation. The Alzheimer's failure is evidence for the first reading. Nobody has run the trial that would settle it, and movement in an Epigenetic clocks reading or another composite aging measure would not settle it either, because a change in a prediction is not a change in an outcome.

§Limitations

Stopping reverses almost everything. The extension of STEP 1 followed participants after withdrawal and found most of the lost weight returning within about a year, with blood pressure and lipid improvements reverting alongside it.⁸ These are therefore chronic medications on the model of antihypertensives, not courses of treatment, and real-world analyses report that a large share of patients stop within the first year because of cost, side effects, or both. An intervention that works only while it is being paid for has a different relationship to healthy lifespan than one that produces a durable change.

A substantial share of the weight lost is lean tissue rather than fat. Body-composition substudies consistently report this, and the proportion is broadly what a caloric deficit of similar size produces by any route, but it is a sharper concern here because the drugs are increasingly used by older adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs with antibodies against the activin and myostatin pathways are underway, and resistance training is the countermeasure with the longest evidence base — one more place where the exercise literature is the comparator any drug has to beat.

§Risks

Gastrointestinal effects dominate the adverse-event profile: nausea, vomiting, diarrhoea, and constipation are common, largely dose-related, and the main reason people discontinue. Gallbladder disease is more frequent with rapid weight loss, and pancreatitis is rare and contested. Delayed gastric emptying has prompted anaesthesiology societies to issue guidance on aspiration risk before elective procedures. Signals raised in observational data are resolved case by case: a rare optic-nerve condition prompted a European safety review that ended in a label change, while other reported associations remain unconfirmed.

The rodent thyroid finding

Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed warning and a contraindication in people with a personal or family history of medullary thyroid carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and no corresponding human effect has been demonstrated. The warning stands because the question is open, not because the finding has been shown to transfer.

§Access and cost

Supply constrained the market for several years after 2021, and in the United States that shortage legally permitted compounding pharmacies to sell copies, an unregulated parallel supply that contracted once the shortages were declared resolved. Price is the binding constraint now. US list prices sit on the order of a thousand dollars a month before rebates, several times what the same products cost in other high-income countries; manufacturers have opened self-pay channels in the mid-hundreds; payers have restricted eligibility or withdrawn coverage for weight indications on budget grounds. Patents on the earlier agents have begun to lapse in some markets, the usual route to a price collapse.

Obesity prevalence is rising fastest in middle-income countries, where these drugs are furthest out of reach, making this a clean current example of the pattern described under Access and inequality: an effective intervention distributed inversely to need. Cosmetic use by people at or near typical weight raises the treatment–enhancement boundary that enhancement ethics has argued over for decades, with the added feature that supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor a consumer metabolic-monitoring market, Continuous glucose monitoring and Wearable health sensors among it, selling the same premise of managed metabolism, while displacing a weight-loss supplement trade built on far weaker evidence.

§Outlook

The pipeline is moving toward oral small molecules that could be manufactured and distributed like ordinary tablets, toward multi-agonists combining GLP-1 with GIP, glucagon, or amylin receptor activity, and toward combinations designed to spare muscle. If oral agents at generic prices arrive, the access argument changes shape and the question becomes what happens when a large fraction of a population takes an appetite-modifying drug indefinitely, a natural experiment with no precedent and no control group.

What remains unanswered is whether any of this shows up where it would count. Population life expectancy responds to metabolic disease with a lag of decades and is confounded by everything else in those decades, so the claim that incretin drugs bought a country years of life will be hard to establish and correspondingly easy to assert. The stronger and more testable claim is narrower: that they compress the years of illness at the end of a life without moving its end, which is Compression of morbidity rather than any change in Maximum human lifespan. That is a large achievement, and it is not the one the popular framing has settled on.

§See also

• Geroscience hypothesis
• Metformin and the TAME trial
• Caloric restriction
• Exercise as a geroprotector
• Healthspan
• Compression of morbidity
• Access and inequality
• Continuous glucose monitoring

§References